Your browser doesn't support javascript.
loading
Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib.
Ikesue, Hiroaki; Yamamoto, Haruna; Hirabatake, Masaki; Hashida, Tohru; Chung, Hobyung; Inokuma, Tetsuro; Muroi, Nobuyuki.
Affiliation
  • Ikesue H; Department of Pharmacy, Kobe City Medical Center General Hospital.
  • Yamamoto H; Department of Pharmacy, Kobe City Medical Center General Hospital.
  • Hirabatake M; Department of Pharmacy, Kobe City Medical Center General Hospital.
  • Hashida T; Department of Pharmacy, Kobe City Medical Center General Hospital.
  • Chung H; Department of Gastroenterology and Hepatology, Kobe City Medical Center General Hospital.
  • Inokuma T; Department of Gastroenterology and Hepatology, Kobe City Medical Center General Hospital.
  • Muroi N; Department of Pharmacy, Kobe City Medical Center General Hospital.
Biol Pharm Bull ; 45(3): 333-338, 2022.
Article in En | MEDLINE | ID: mdl-35228399
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinolines / Carcinoma, Hepatocellular / Liver Neoplasms / Antineoplastic Agents Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Biol Pharm Bull Journal subject: BIOQUIMICA / FARMACOLOGIA Year: 2022 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinolines / Carcinoma, Hepatocellular / Liver Neoplasms / Antineoplastic Agents Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Biol Pharm Bull Journal subject: BIOQUIMICA / FARMACOLOGIA Year: 2022 Document type: Article Country of publication: